Trade Report: The Oppenheimer Holdings Inc. Reiterates Hold Rating for Opko Health Inc. (OPK)

The Oppenheimer Holdings Inc. Reiterates Hold Rating for Opko Health Inc. (OPK)

Oppenheimer Holdings Inc. reissued their hold rating on shares of Opko Health Inc. (NYSE:OPK) in a research note published on Monday morning.

A number of other analysts have also recently weighed in on OPK. Zacks Investment Research cut Opko Health from a hold rating to a sell rating in a research report on Friday, July 1st. Jefferies Group reaffirmed a hold rating on shares of Opko Health in a research report on Wednesday, August 17th. Standpoint Research increased their price objective on Opko Health from $16.00 to $18.00 and gave the stock a buy rating in a research report on Tuesday, June 21st. Deutsche Bank AG decreased their price objective on Opko Health from $11.00 to $10.00 and set a hold rating for the company in a research report on Thursday, June 16th. Finally, JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the stock a buy rating in a research report on Tuesday, August 9th. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus price target of $13.20.

Shares of Opko Health (NYSE:OPK) opened at 9.56 on Monday. The stock has a market capitalization of $5.26 billion and a PE ratio of 40.00. Opko Health has a 52-week low of $7.12 and a 52-week high of $11.85. The stock has a 50 day moving average price of $10.07 and a 200-day moving average price of $10.08.

Opko Health (NYSE:OPK) last announced its earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.05. The firm earned $357.10 million during the quarter, compared to analyst estimates of $324.11 million. The firm’s revenue for the quarter was up 742.2% compared to the same quarter last year. During the same period last year, the company earned ($0.09) earnings per share. On average, equities research analysts anticipate that Opko Health will post ($0.05) EPS for the current fiscal year.

In other news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 2nd. The stock was purchased at an average cost of $9.88 per share, with a total value of $98,800.00. Following the purchase, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $30,321,235.88. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC purchased a new position in Opko Health during the second quarter valued at $100,000. Financial Architects Inc increased its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in Opko Health during the second quarter valued at $103,000. Williams Jones & Associates LLC increased its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock valued at $106,000 after buying an additional 8,800 shares during the last quarter. Finally, Nuveen Fund Advisors LLC purchased a new position in Opko Health during the second quarter valued at $131,000.

Opko Health Company Profile

Related posts

Leave a Comment